Beam Therapeutics | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Company Directory for Beam Therapeutics

Team Bitscale

12 Feb 2026 — 1 min read

Beam Therapeutics

Overview

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in precision genetic medicines through advanced gene editing technologies. Founded in 2017 by scientists from the Broad Institute of MIT and Harvard, the company focuses on CRISPR base editing and prime editing to develop therapies for serious diseases. The company went public in February 2020, raising $180 million, and has since built a fully integrated platform combining gene editing, delivery technologies, and internal manufacturing capabilities.

Its proprietary base editing technology enables precise DNA modifications without double-strand breaks, offering targeted genomic changes for genetic disorders. Programs span gene therapy, precision medicines, hematology, immunology, and cell therapy. Revenue comes primarily via licensing and collaboration agreements with partners such as Pfizer and Lilly. Beam is dedicated to delivering lifelong cures for genetic diseases through cutting-edge research and innovation.

Basic Information

Industry	research
Founded	2017
Revenue	$63.5M
Headquarters	238 Main St, Cambridge, Massachusetts 02142-1008, United States
Alexa Ranking

Contact Details

Key Focus Areas & Initiatives

Precision genetic medicines
Gene therapy development
CRISPR/Cas9 base editing
Prime editing technology
Molecular therapeutics for rare diseases
Genetic mutation correction
Collaborative research with Pfizer and Lilly
Internal manufacturing platform
Cell therapy advancement
Hematology and immunology research
Targeted genome rewriting
RNA and DNA modification
Innovative delivery technologies
Lipid nanoparticle and vector production
Clinical-stage biotech pipeline

Technologies Used

.GIS
.NET
AWS Glue Data Catalog
Amazon S3
Amazon Virtual Private Cloud (Amazon VPC)
BASE
Basis
Boomi
CAT
Coupa
DeltaV
EasyDNS
Electron
Flow
Homestead
IDC
ISO+™
LabVantage
Lambda Cloud
MeridianLink Mortgage
Micro
Microsoft Office
Mimecast
NEAR
Olo
R
REST
Redshift
Remote
Resi
SAP
SAS Enterprise Guide
Salesforce
Salesforce CRM Analytics
Sizmek (MediaMind)
Slack
Smartsheet
Thermo Scientific Chromeleon Chromatography Data System (CDS)
Veeva Systems
WP Engine
eMaint CMMS

Affiliated Organizations & Regional Branches

Guide Therapeutics

GTM Strategy: The Complete Guide (Framework, Examples & B2B Playbook)

Most things labeled a “GTM strategy” are really a channel checklist wearing a nice slide template. They are activity plans, not a coherent answer to how the business will create, capture, and deliver value for a specific buyer in a specific market. This is written for B2B founders, product marketers,

How Scrut.io Built a Compliance-Signal GTM Machine with Bitscale

Scrut Automation simplifies continuous compliance for cloud-native companies, helping them achieve ISO 27001, SOC 2, PCI DSS, and GDPR compliance 5x faster — with real-time risk monitoring and automated evidence collection.

Clay API Limits, Authentication & Rate Limits Explained

Your enrichment workflow ran perfectly on 50 test records. Then you pointed it at 10,000 contacts and everything collapsed: 429 errors, duplicate CRM writes, and a credit balance that evaporated overnight. The Clay API usually is not the root cause. The root cause is treating authentication, rate limits, and

GTM Data Stack for US Outbound Teams

Outbound has changed. Spray-and-pray cadences that worked five years ago now burn through contact lists, damage sender reputation, and leave revenue teams short on pipeline. What separates high-performing US outbound teams in 2026 is not effort or headcount. It is the quality, governance, and architecture of the GTM Data Stack.